Local manufacturing starts with a market—not a machine.
A production line can create capacity. It cannot, by itself, create a sustainable diagnostic supply system. Long-term localisation depends on whether public-health priorities, purchasing demand, regulation, quality, workforce capability, suppliers and technology transfer are designed to work together.
WHO reported that more than 200 representatives from governments, regulators, industry, finance, academia and international organisations met at the 2026 Private Sector Engagement Forum in Cairo. The central conclusion was that sustainable local manufacturing cannot be achieved by investing in production facilities alone. WHO identified regulatory systems, skilled people, quality management, research and innovation, reliable suppliers, sustainable finance and predictable markets as interconnected requirements.
The factory is one node in the system
Manufacturing projects are often described through visible assets: floor area, clean rooms, production equipment, output per hour and installation schedules. Those assets matter, but they become productive only when the surrounding system can select appropriate products, purchase them consistently, regulate them competently, release conforming lots and sustain operations after the initial project phase.
Vision interpretation: for diagnostics, the correct planning unit is not the production line. It is the complete pathway from defined health need to an authorised, quality-controlled product that can be purchased, supplied, used and supported reliably.
Predictable demand is technical infrastructure
WHO's account of the Cairo forum describes predictable demand as a prerequisite for sustainable manufacturing. It identifies market-shaping initiatives, pooled procurement and long-term purchasing commitments as mechanisms that can strengthen market sustainability. The same report describes regional regulatory convergence and market integration as ways to reduce fragmentation and create larger, more predictable markets.
Demand forecasting is therefore more than a commercial spreadsheet. It determines batch size, raw-material commitments, workforce utilisation, stability planning, maintenance budgets and the cost of keeping quality functions active. A project designed only around peak emergency demand may create impressive nominal capacity while leaving the facility underused between outbreaks.
A stronger model combines routine diagnostic demand with defined surge scenarios. Routine production keeps skills, suppliers, equipment and quality processes active. Surge planning then establishes which products, materials, staff and authorised release pathways can expand when public-health demand changes.
Six gates before equipment procurement
Vision interpretation: a responsible diagnostic-localisation programme should pass six connected gates before its equipment list is treated as final.
- Public-health and market need: define the priority testing pathways, expected users, annual demand, procurement channels and realistic surge requirement.
- Portfolio fit: select products that match the laboratory network, infrastructure, specimen pathways and purchasing environment—not simply the technologies that are easiest to install.
- Regulatory and evidence route: map product classification, legal-manufacturer responsibilities, local representation, performance evidence, labelling, registration and post-market obligations.
- Quality-transfer architecture: define the controlled documents, acceptance criteria, training, process verification, lot release, deviation handling, change control and quality agreements that must move with the technology.
- Supply and service continuity: qualify critical materials and suppliers, plan import and cold-chain dependencies, and provide maintenance, calibration and replacement strategies.
- Operating sustainability: model working capital, utilisation, workforce retention, quality overhead, realistic pricing and demand continuity after grants or mobilisation budgets end.
Technology transfer must transfer decisions—not only instructions
WHO states that successful technology transfer extends beyond manufacturing processes or intellectual property. It requires institutional capabilities that include quality management, regulatory expertise, operational excellence, scientific know-how and innovation capacity. WHO's Technical Advisory Group on Local Production and Technology Transfer similarly treats financing, market conditions, human capital, infrastructure, research, production capability and partnerships as parts of the same ecosystem.
A production procedure explains what to do under expected conditions. A mature transfer also explains how to recognise loss of control, investigate a deviation, assess a supplier change, interpret a trend and decide whether a lot can be released. These decision systems are what allow local teams to operate responsibly after the transfer team leaves.
For an in vitro diagnostic, a change in a raw material, manufacturing site, software version, packaging configuration, stability claim or release method may require documented assessment and, depending on the applicable pathway, regulatory action. Localisation should therefore preserve traceability between the transferred product, its evidence, the active process and every authorised claim.
Regional manufacturing is an access strategy
FIND describes diagnostic manufacturing as highly concentrated among a limited number of companies in Asia, North America and Europe. Its regional-manufacturing programme links more distributed capacity to universal health coverage and outbreak preparedness, while also noting that sustainable facilities require coordination across the diagnostic value chain, quality systems, regulatory authorisation and market entry.
Vision interpretation: local production creates public-health value when it improves dependable access to appropriate diagnostics without lowering the evidence or quality threshold. Local content percentage, installed capacity or country-of-origin labelling should not be used as substitutes for product suitability, controlled manufacture or regulatory compliance.
The Vision Biotechnology response lens
Vision Biotechnology approaches localisation as a phased capacity-building programme. The first phase should establish the health need, market case, partner responsibilities and authority pathway. The second should define the facility, technology-transfer package, quality system, workforce and supplier model. The third should move through training, process verification, pilot production, documented review and authorised release readiness. The final phase should measure routine performance, supply resilience, quality trends and the programme's ability to scale responsibly.
This framework does not guarantee feasibility, registration, procurement, capacity or commercial success. Each project requires product-specific technical review, evidence assessment, country-specific regulatory analysis and a realistic operating plan agreed by the responsible parties.
Do not begin localisation by asking how many units a line can produce. Begin by asking which health need the programme will serve, who will buy its products, how quality will be demonstrated, which authority will oversee them, and how the system will remain operational after installation.
Primary sources
This article clearly separates source-published information from Vision Biotechnology interpretation. It provides general manufacturing, quality-system and localisation perspectives; it is not a product claim, regulatory approval, procurement recommendation, legal advice or guarantee of project feasibility. Applicable authority decisions and product-specific evidence remain controlling.